2025年8月26日，博硕科技(300951.SZ)发布2025年半年度报告。截至2025年8月25日，共有8个机构投资 者披露持有博硕科技A股股份，合计持股量达9529.04万股，占博硕科技总股本的56.22%。其中，机构 投资者包括江苏摩锐投资有限公司、宿迁市鸿德轩投资合伙企业(有限合伙)、大家人寿保险股份有限公 司-万能产品、中国工商银行股份有限公司-金鹰科技创新股票型证券投资基金、北京银行股份有限公司- 鹏华双债加利债券型证券投资基金、中国农业银行股份有限公司-鹏华可转债债券型证券投资基金、北 京市(柒号)职业年金计划-建设银行、香港中央结算有限公司，机构投资者合计持股比例达56.22%。相 较于上一季度，机构持股比例合计下跌了0.53个百分点。 公募基金方面，本期较上一季度新披露的公募基金共计3个，包括金鹰科技创新股票A、鹏华双债加利 债券A、鹏华可转债债券A。本期较上一季未再披露的公募基金共计2个，包括博道远航混合A、博道成 长智航股票A。 对于社保基金，本期较上一季未再披露的社保基金共计1个，即汇添富基金管理股份有限公司-社保基金 1802组合。 外资态度来看，本期较上一季度持股减少的外资基金共 ...

Core Insights - The article discusses the performance and challenges faced by Penghua Fund in the public fund industry, highlighting its strong returns in both equity and fixed income sectors while also addressing its declining revenue and market share [4][10][12]. Group 1: Performance Highlights - Penghua Fund has achieved significant success in the active equity sector, with multiple products ranking at the top over various time frames, including a 96.93% return for Penghua Medical Technology Stock A over the past year [4][6]. - The fund's fixed income team has also delivered impressive results, with Penghua Yong'an Bond Fund showing a 3.76% return over the past year, ranking 206 out of 2757 funds [7]. - The overall market recovery and the fund's diversified product offerings have contributed to its strong performance, showcasing the expertise of its fund managers [8][10]. Group 2: Revenue and Market Challenges - Despite strong performance, Penghua Fund has faced declining revenues, with a reported revenue of 3.594 billion yuan in 2024, down 8.94% year-on-year, marking the third consecutive year of decline [10][11]. - The fund's management scale has only increased by 11.21% over two and a half years, lagging behind the industry average growth of 31.54% during the same period [11][12]. - The decline in the scale of equity and mixed funds managed by Penghua Fund has resulted in a significant drop in its market position, falling out of the top tier in the public fund industry [12][15]. Group 3: Strategic Shifts and Future Outlook - The article emphasizes the need for the fund industry to shift focus from scale-driven growth to long-term value creation and investor interests, as highlighted by the new floating fee rate fund initiative [18][19]. - Penghua Fund is adapting to these changes by emphasizing professional platform development and focusing on long-term investment strategies, as seen in the performance of its floating fee products [19][20]. - The growth of the ETF market presents an opportunity for Penghua Fund to enhance its competitive position, although it faces challenges with many of its ETF products being underfunded [23][24].

公募基金方面，本期较上一期持股增加的公募基金共计18个，主要包括易方达医药生物股票A、鹏华双 债加利债券A、鹏华可转债债券A、农银医疗保健股票、长城大健康混合A等，持股增加占比达3.19%。 本期较上一季度持股减少的公募基金共计11个，主要包括富国精准医疗灵活配置混合A、鹏华品牌传承 混合、招商景气优选股票A、富国高新技术产业混合、鹏华产业精选混合A等，持股减少占比达 0.54%。本期较上一季度新披露的公募基金共计16个，主要包括富国新机遇灵活配置混合A、易方达大 健康主题混合、华富健康文娱灵活配置混合A、建信高端医疗股票A、中航优选领航混合发起A等。本 期较上一季未再披露的公募基金共计107个，主要包括鹏华汇智优选混合A、汇添富医疗服务灵活配置 混合A、鹏华创新未来混合(LOF)、汇添富达欣混合A、宝盈医疗健康沪港深股票A等。 2025年4月30日，热景生物(688068.SH)发布2025年第一季报。截至2025年4月30日，共有55个机构投资 者披露持有热景生物A股股份，合计持股量达2869.52万股，占热景生物总股本的31.03%。其中，前十 大机构投资者包括青岛同程热景企业管理咨询合伙企业(有限合伙 ...